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Structural characterization of 
human Vaccinia-Related Kinases 
(VRK) bound to small-molecule 
inhibitors identifies different P-loop 
conformations
Rafael M. Couñago  1,2, Charles K. Allerston3, Pavel Savitsky3, Hatylas Azevedo4,  
Paulo H. Godoi1,5, Carrow I. Wells6, Alessandra Mascarello4, Fernando H. de Souza Gama4, 
Katlin B. Massirer1,2, William J. Zuercher6, Cristiano R. W. Guimarães4 & Opher Gileadi1,3
The human genome encodes two active Vaccinia-related protein kinases (VRK), VRK1 and VRK2. These 
proteins have been implicated in a number of cellular processes and linked to a variety of tumors. 
However, understanding the cellular role of VRKs and establishing their potential use as targets for 
therapeutic intervention has been limited by the lack of tool compounds that can specifically modulate 
the activity of these kinases in cells. Here we identified BI-D1870, a dihydropteridine inhibitor of RSK 
kinases, as a promising starting point for the development of chemical probes targeting the active 
VRKs. We solved co-crystal structures of both VRK1 and VRK2 bound to BI-D1870 and of VRK1 bound 
to two broad-spectrum inhibitors. These structures revealed that both VRKs can adopt a P-loop folded 
conformation, which is stabilized by different mechanisms on each protein. Based on these structures, 
we suggest modifications to the dihydropteridine scaffold that can be explored to produce potent and 
specific inhibitors towards VRK1 and VRK2.
Members of the Vaccinia-related kinase (VRK) family of serine/threonine protein kinases are present in the 
genomes of all metazoans and those of poxviruses, including the family-founding member vaccinia virus B1R1–6. 
The human genome encodes three VRK proteins. VRK1 is a nuclear kinase implicated in cell cycle control, 
chromatin condensation and transcription regulation, and its substrates include p53, Activating Transcription 
Factor 2 (ATF2), Activator Protein 1 transcription factor (c-Jun), Barrier to Autointegration Factor (BANF1) 
and histone H37–14. VRK1 function is linked to cell proliferation and its overexpression has been associated with 
tumor growth14–17. VRK2 is an active kinase that displays two alternative splicing forms, each of which localizes 
to distinct cellular compartments (cytoplasm and nucleus or ER and mitochondria)18. The alternatively spliced 
C-terminal domain interacts with and regulates components of the JNK signal pathway (JIP-1, TAK1 and MKK7) 
and BHRF1, the BCL2 homolog in Epstein-Barr virus, independent of kinase activity19–21. p53 and BANF1 are 
also substrates for VRK218, 22. VRK2 is also implicated in mitochondrial-mediated apoptosis23. The third VRK 
family member, VRK3, is not catalytically competent and is thus classified as a pseudokinase. VRK3 can bind and 
activate VHR, the phosphatase responsible for inhibiting the ERK signaling pathway8, 10, 24.
The VRKs belong to the CK1 kinase group, whose members typically include additional structural elements 
within the conserved kinase fold. Crystal structures are available for the ligand-free kinase domains (KD) of 
VRK2 and VRK325. A ligand-free, solution NMR structure is available for a C-terminal truncation of VRK1 
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containing the kinase domain and most of the regulatory C-terminal domain26. These structures revealed that 
all three human VRKs have the canonical kinase fold and possess a unique helix (αC4) between αC and β4. 
This helix links the two lobes of the kinase and is thought to maintain the VRK proteins in a closed conforma-
tion, characteristic of an activated state25. VRK3 has a similar fold to VRK1 and VRK2 but displays a degraded 
ATP-binding site25. The kinase domains of active human VRKs are similar to each other (~80% sequence identity) 
but only distantly related (<30% sequence identity) to those of other members of the CK1 kinase group.
In addition to the catalytic domain, VRK1 and VRK2 have large, non-catalytic C-terminal regions, which 
in VRK1 contains putative regulatory autophosphorylation sites26, 27. The solution structure of VRK1 revealed 
that this region interacts with residues from the protein ATP-binding pocket and activation segment26. Ser/
Thr residues within this region are phosphorylated10, an event that may be necessary for the dissociation of the 
C-terminal domain from the ATP-binding pocket and activation of VRK1. Much less is known about the struc-
ture of the C-terminal domain of VRK2 and its impact on the kinase activity.
Here we present the first crystal structures of the kinase domain of VRK1 and the first crystal structures for 
ligand-bound VRK1 and VRK2. Our results reveal the structural changes necessary for the displacement of VRK1 
C-terminal region by ATP-competitive inhibitors and suggest specificity determinants that may be employed to 
design small-molecule inhibitors selective for the two active human VRKs.
Results
Identification of potent VRK ligands. Previous studies using large libraries of diverse ATP-competitive 
inhibitors failed to identify potent hit compounds for VRK125, 28. To widen the scope of potential ligands, we 
analyzed previous results from thermal-shift assays (DSF) using VRK13-364 and the published kinase inhibitor 
set (PKIS)29. VRK2 was not included in the PKIS characterization study. For VRK13-364, 29 compounds displayed 
changes in melting temperatures, ΔTm, larger than 2.0 °C (an arbitrary cut off for a positive hit in this experi-
ment29), with the top hit, GW297361X, displaying a ΔTm of 9.7 °C (Fig. 1a; Supplementary Table S1). Compared 
to the other 67 kinases in the PKIS panel, VRK1 showed a relatively small number of hit compounds (Fig. 1a,b). 
Compounds displaying the highest ΔTms were quite promiscuous, as reflected by their low Gini coefficient 
(Fig. 1c). The Gini coefficient is a measure of compound selectivity, with values close to 1 representing highly 
selective compounds30. The top hit GW297361X had a Gini coefficient of 0.4.
Within the PKIS, VRK13-364 interacted mostly with broad spectrum compounds from an oxindole series 
derived from a medicinal chemistry program targeting CDK2 inhibitors31. The PKIS data was also used in a 
hierarchical clustering (HCL) analysis to identify kinases with binding preferences similar to that of VRK1. These 
Figure 1. Analysis of published thermal shift assay (DSF) screening data for VRK1-PKIS. (a) Heat map 
showing DSF screening data for PKIS compounds with ΔTm > 2.0 °C for VRK1 (black box) together with the 
results for other 67 kinases (x-axis). Compounds were ranked (top to bottom) according to decreasing ΔTm 
for VRK1. Background color indicates ΔTm as a gradient from 2.0 °C (yellow) to the maximum observed ΔTm 
for each protein (red). Light blue background color indicates ΔTm < 2.0 °C. (b) Graphic showing number of 
PKIS compounds with ΔTm > 2.0 °C (y-axis) for VRK1 (red circle) and other 67 tested kinases (x-axis, black 
circles). (c) Graphic showing the poor relationship between ΔTm and Gini (selectivity) coefficients for PKIS 
compounds interacting with VRK1. The top 3 VRK1 hits are highlighted.
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studies revealed that the best VRK1 hit compounds also induced large ΔTm shifts on kinases such as CDK2 and 
TNIK (Supplementary Figure S1). A structure-activity relationship analysis of oxindoles within PKIS suggested 
the sulfur atom in GW297361X thiazole ring and polar substituents at the 6-position might be important for 
VRK1 interaction (Table 1).
Because the oxindole series in the PKIS showed poor kinase specificity, we sought to identify other poten-
tial inhibitors. Specifically, we performed a DSF screen on purified VRK13-364 and VRK214-335 using a commer-
cially available library of 378 chemically diverse, bioactive, ATP-competitive, kinase inhibitors (Supplementary 
Table S2). To compare these results with those previously obtained for the PKIS compounds, we included 
GW297361X, the top VRK1 hit from PKIS, to the experiment. Note that the absolute ΔTm values for 
GW297361X differ between this and earlier experiments, possibly because of the use of different detection rea-
gents and experimental setups.
The changes in melting temperature, ΔTm, for active VRKs spanned a broad range of values. However, 
we found only a limited number of compounds with high ΔTm values for VRK1 and VRK2 (Fig. 2a,b and 
Supplementary Table 2) when compared to other protein kinases such as AAK1 (AP2-associated kinase 1; 
included for comparison) (Fig. 2c). For both VRK13-364 and VRK214-335, the compound inducing the largest ΔTm 
shift was BI-D1870, a dihydropteridinone inhibitor originally developed for p90 RSK (ribosomal S6 kinase)32 
which displayed more substantial temperature stabilization than the best PKIS hit for VRK13-364, GW297361X 
(5.5 versus 3.9 °C in this experiment, respectively). Within the identified compounds, four were able to induce 
ΔTm > 2.0 °C for both VRKs, whereas three hits were exclusive to VRK1 and six hit compounds were exclusive 
to VRK2 (Fig. 2d). BI-D1870 was described as selective for RSK/N-terminal kinase domain and PLK1 (polo-like 
kinase 1)32, but this report was based on a limited number of protein kinases. To understand the ligand binding 
site of active VRK proteins, we crystallized them in the presence of BI-D1870, the top DSF hit from the com-
mercial library identified here. We also crystallized VRK1 with the top hit from PKIS GW297361X29 and with 
broad spectrum kinase inhibitor ASC24 (compound 3 in ref. 33). The three compounds used in crystallization 
are shown in Fig. 2e.
Overall structure of ligand-bound active human VRKs. The ligand-free kinase domain of VRK2 has 
been crystallized previously25. To crystallize VRK1, we mutated surface residues to reduce the entropic cost of 
crystallization34. We obtained crystals of a construct containing the kinase domain and part of the regulatory 
C-terminal tail (residues 3-364) and four clusters of surface entropy reduction mutations (K34A/K35A/E36A; 
E212A/K214A/E215A; E292A/K293A/K295A and K359A/K360A) (Supplementary Figure S2a). All four mutated 
clusters seem to contribute to crystallization as proteins mutated at only three of the clusters failed to crystallize. 
We then obtained co-crystal structures of VRK13-364 bound to the three ligands - ASC24, GW297361X, and 
BI-D1870 (Fig. 2e); as well as of VRK214-335 in the presence of BI-D1870. All structures were determined by 
molecular replacement and refined to resolutions between 2.0 and 2.4 Å (Table 2). For VRK1/ligand models, lack 
of electron density prevented model completion for some residues at the protein termini and the glycine-rich 
P-loop in some polypeptide chains, likely because they are disordered in the crystal structures. The most com-
plete VRK13-364/ASC24 model contains residues 21–46 and 48–341 (chain A); and the one for the VRK13-364/
BI-D1870 complex contains residues 20–43, 49–341 (chain A). The VRK13-364/GW92761X structure has a less 
ordered N-terminal domain and in two of the crystal polypeptide chains (C and D) models start after the protein 
P-loop region (residues 68 or 80). Nevertheless, the most complete polypeptide chain in this model contains an 
intact P-loop (chain A, residues 22–341; used for the structural comparisons below). The VRK214-335/BI-D1870 
model contains residues 14–328 and also has a complete P-loop.
Figure 3 shows ligand-bound VRK13-364 and VRK214-335 proteins (Fig. 3a–d). All ligands bind to the 
ATP-binding pocket of the proteins. Ligand-bound VRK kinase domains adopt the canonical protein kinase fold, 
except for the presence of the additional α-helix between αC and β4 (αC4) exclusively found on VRK proteins. 
The equivalent region in VRKs’ closest structural homolog, casein kinase 1 (CK1) is a short loop35 (Fig. 3e). 
VRK13-364/ligand structures suggest the protein N-terminal region is quite dynamic, especially in the P-loop 
region (Fig. 3f). Structural comparisons of ligand-bound crystal structures and the structures of apo-VRK1 
obtained by NMR in solution further suggest the protein N-terminal and P-loop regions are dynamic (Fig. 3g and 
Supplementary Figure S3).
Previous VRK structures revealed that αC4 plays a major role in stabilizing the closed, active conformation of 
the VRKs. In the active conformation, the kinase domain N- and C-terminal lobes are in proximity to each other 
and a conserved Tyr residue from the DYG motif (DFG in most kinases) within the activation segment stabilizes a 
catalytically necessary ion pair between conserved lysine and glutamate residues25, 26. In most protein kinases, this 
closed conformation is only achieved following phosphorylation of regulatory sites in the activation segment. In 
the VRKs, however, these phosphorylation events are not necessary as αC4 promotes extensive contacts between 
N- and C-terminal lobes. The ligand-bound structures obtained here for active VRKs are in a closed, active 
conformation and display the same overall organization previously observed for the apo-structures, including 
the position of the VRK-exclusive αC4 (Fig. 3g–h) and the structural organization of conserved residues that 
make up the kinase hydrophobic spine36 (Supplementary Figure S2a,b). As for VRK1, changes between apo- and 
ligand-bound VRK2 structures are mostly located in the N-terminal and P-loop regions of the protein (Fig. 3h).
Ligands can induce a folded P-loop conformation in the VRKs. The glycine-rich P-loop (GxGxF/YG 
motif) is located between the β-1 and β-2 strands and interacts with the phosphate groups in ATP, positioning the 
nucleotide for catalysis. In the absence of ATP, this region is mostly disordered due to the conformational flexibil-
ity conferred by glycine residues. The P-loop was disordered in the previously published apo-VRK2 crystals25 and 
in most polypeptide chains within VRK1/ligand crystals reported here. Kinase structures with an intact P-loop 
usually show this region in an extended conformation. In a small number of kinases, specific ATP-competitive 
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PKIS compound Molecular structure VRK1 ΔTm (°C)
GW297361X 9.7
GW290597X 6.0
GW300660X 4.8
GW305178X 4.7
GW300657X 4.2
GW416981X 3.6
GW275944X 0.5
GW300653X 0.1
GW396574X 0.1
GW352430A 0.0
Table 1. Structure-activity relationship of selected compounds from the oxindole series.
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inhibitors can induce the P-loop to adopt a so-called folded or closed conformation. In this unusual configura-
tion, P-loop residues close over the ligand and shield it from the solvent. The larger contact surface provided by 
the folded P-loop conformation has been associated with favorable inhibitor selectivity. But, so far, no obvious 
factor – or combination of factors; has been predictive of this conformation in kinases. Nevertheless, the presence 
of conserved F or Y residues seems to be critical for the stabilization of the P-loop folded structure via π-π and 
hydrophobic interactions with the ligand37.
The P-loop locates to residues 44 to 49 in VRK1 and 36 to 41 in VRK2. In both proteins, the conserved aro-
matic residue in this region is a phenylalanine. The crystal structures of VRK13-364/GW297361X (chain A) and 
VRK214-335/BI-D1870 reveal that the glycine-rich P-loop region of these kinases can adopt the so-called folded 
conformation. Nevertheless, the folded conformation of the P-loop is stabilized by different types of interactions 
in VRK1 and VRK2 kinase domains (Fig. 4). In the VRK13-364/GW297361X structure, the folded conformation 
of the P-loop is stabilized by a sulfur-π interaction between Phe48 and the sulfur atom in the thiazole moiety 
of GW297361X (Fig. 4a). Other than this interaction, VRK13-364 P-loop residues do not contact atoms in the 
compound (Fig. 4a–d). By contrast, in VRK214-335, both main chain and side chain atoms in the P-loop are in 
close proximity to atoms from the compound. However, the side chain of the conserved aromatic residue in the 
P-loop of VRK2 (Phe40) could not be modeled due to lack of electron density - an indication that this residue 
is disordered (Fig. 4e–h). Thus, the folded conformation of the P-loop in VRK2 seems to be driven mostly by 
shape complementarity and hydrophobic contacts between the protein and the compound, whereas in VRK1 the 
P-loop folded conformation is held in place by a direct interaction between the ligand sulfur atom and the protein 
aromatic residue. Moreover, the co-structure of VRK13-364 bound to BI-D1870 revealed this compound cannot 
stabilize a P-loop folded conformation in this protein. These findings indicate the molecular bases for binding of 
small molecules and for stabilizing the P-loop folded conformation in VRK1 and VRK2 are different.
Small molecule binding by VRK1 and VRK2 can also be distinguished by the precise positioning of the folded 
P-loop over the ATP-binding pocket. The folded P-loop of VRK2 points towards αC and fits under residues 
from loop β3-αC (Fig. 4g,h). By contrast, in VRK1, the folded P-loop points towards the solvent and the β3-αC 
loop points away from the P-loop, creating a small cavity between the P-loop and αC (Fig. 4c,d). Thus, despite 
the high sequence similarity between the ATP-binding pockets of the VRK1 and VRK2 kinase domains, these 
structural rearrangements provide subtle differences that can be exploited during the development of specific 
VRK inhibitors.
Crystal contact analyses suggested that these did not play a direct role in the observed conformation of VRK1 
or VRK2 P-loop regions. For VRK1, there are no protein atoms (including from symmetry-related molecules) 
within a 4.5 Å radius of any atom in the P-loop. In VRK214-335/BI-D1870 crystals, a similar analysis identified 
only three atoms (from the side chain of residue Pro319 from a symmetry-related molecule) (Supplementary 
Figure S4a,b). It is thus fair to assume that the observed folded P-loop conformations are stabilized by direct 
interactions with the ligands and not due crystal contacts.
Figure 2. DSF screening identified few hit compounds for active VRKs. Heat maps showing DSF screening 
data for (a) VRK1, (b) VRK2 and (c) AAK1 (included for comparison) versus a 378-compound library of 
cell-permeable, bioactive kinase inhibitors. The color scheme is the same as in Fig. 1a. Panels indicate rows 
(x-axis) and lines (y-axis) in a 384-well plate. Numbers show the observed ΔTm shift in degrees Celsius. (d) Bar 
graph showing ΔTm (°C) for top hit compounds for VRK1 (blue bars) and VRK2 (orange bars). (e) The three 
compounds used in crystallization. BI-D1870 was used as a racemic mix; the chiral carbon is marked with a star.
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Molecular bases for ligand specificity. Our aim was to identify a strategy to generate VRK1- and 
VRK2-selective inhibitors and our crystal structures reveal distinct structural features that may be explored to 
this end.
The binding of BI-D1870 suggests one approach that may be used to develop selective molecules for VRK2. 
BI-D1870 adopts a non-planar conformation that complements well the ATP-binding site of VRK2. BI-D1870 
is synthesized as a racemic mixture. However, the VRK2/BI-D1870 co-structure revealed this protein favors a 
particular enantiomer of BI-D1870 (S-form) and that the methyl group attached to the stereogenic center pro-
jects into a cavity formed by the hydrophobic side chains from P-loop residues. The pendant isopentyl group in 
the bicyclic core is orthogonal to the plane of the ring in a configuration that allows Gly39 from the P-loop to 
approach Asp186 in the DYG motif, closing the P-loop over the compound 3,5-difluoro-4-hydroxyphenyl ring 
(Fig. 4e–h). Structural comparisons of ligand-bound and apo-VRK2 structures reveal the isopentyl moiety also 
orients the side chain of Asp186 towards the catalytic lysine. The compound 3,5-difluoro-4-hydroxyphenyl sub-
stituent induced further rearrangements in this region of the protein. For example, the gatekeeper methionine 
is displaced and the catalytic lysine re-positions itself to become the focal point in a network of polar contacts 
that also involves the phenol of BI-D1870 and the side chains of Asp186 and that from the conserved glutamate 
residue in αC, Glu73 (Fig. 5a). Residue Tyr77 in the αC helix also participates in this network via water-mediated 
hydrogen bonds to BI-D1870 and Glu73.
Combined, the three VRK1 co-structures obtained here suggest strategies for the development of selec-
tive molecules for this protein (Fig. 5b–f). These co-structures revealed VRK1 N-terminal domain to be quite 
dynamic, whereas the protein C-terminal lobe displays a more rigid architecture (Fig. 3f). Ligand GW297361X 
can stabilize the protein N-lobe via a sulfur-π interaction with P-loop residue Phe48. In this position, the side 
chain of Phe48 approaches those of Asp197 in the DYG motif and Asn182 at the ATP-binding site entrance 
to create a hydrophobic tunnel over the compound (Fig. 4a,b). Another important interaction facilitated by 
GW297361X involves the sulfonamide group and residues located just outside the hinge region (Fig. 5b). The 
VRK1 binding pocket accommodates compound ASC24 in a tear-drop conformation and groups at opposite 
ends of the molecule reach towards residues in the protein P-loop. Despite these interactions, ASC24 does not 
support a P-loop folded conformation, most likely due to steric effects with P-loop residue Phe48 (Fig. 5c). Finally, 
Protein VRK1A VRK1 VRK1 VRK2
Ligand ASC24 BI-D1870 GW297361X BI-D1870
Data collection
X-ray source DLS I02 DLS I03 DLS I02 LNLS W01B-MX2
Wavelength (Å) 0.9790 0.9763 0.9795 1.4587
Space group P212121 P212121 P212121 P212121
Cell dimensions (Å)
a, b, c (Å) 93.0, 97.2, 191.2 92.2, 95.2, 191.8 92.1, 96.0, 192.6 54.5, 72.7, 83.0
Resolution (Å)* 46.3–2.4 29.7–2.0 29.6–2.4 28.4–2.0
No. of unique reflections 
overall * 67,821 (4,864) 111,044 (5,602) 67,658 (4,493) 22,504 (1,633)
Rmerge (%)* 0.11 (0.5) 0.05 (0.7) 0.08 (0.7) 0.06 (0.7)
Mean I/σI * 7.8 (3.4) 14.3 (2.0) 14.2 (2.3) 13.8 (2.8)
Completeness (%)* 98.9 (98.6) 97.1 (99.5) 99.9 (80.7) 98.4 (97.9)
Redundancy* 3.5 (3.4) 6.2 (3.7) 6.5 (6.6) 5.3 (5.5)
Refinement
Resolution (Å) 46.3–2.4 29.7–2.0 14.2–2.4 28.4–2.0
Rcryst/Rfree (%) 21.2/24.9 17.3/20.4 17.7/21.4 18.2/22.1
No. protein atoms 9, 754 9, 597 9, 154 2, 391
No. ligand atoms 132 170 149 28
No. solvent atoms 900 683 551 137
Mean B-factor (Å) 46.2 52.9 60.1 42.6
Rmsd bond lengths (Å) 0.009 0.010 0.010 0.010
Rmsd bong angles 
(degrees) 0.97 1.00 1.08 1.03
Ramachandran statistics (%)
Favored 97.3 98.3 98.4 98.1
Allowed 2.7 1.7 1.6 1.9
Outlier 0 0 0 0
PDB ID 3OP5 5UVF 5UKF 5UU1
Crystallization conditions
20% PEG 
3350, 0.2 M K/
Na(tartrate) 
pH 7.0
25% PEG 3350, 
0.1 M bis-tris 
pH 6.5, 0.2 M 
lithium sulfate
27.5% PEG 
3350; 0.3 M 
AmSO4; 0.1 M 
HEPES pH 7.0
22.5% PEG 3350, 
20 mM magnesium 
chloride, 0.1 M 
CHC buffer pH 7.5
Table 2. Crystallographic data.
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BI-D1870 is seen in two different poses, supported by distinct hinge-binding modes. Both poses only loosely 
complement the volume of the ATP-binding pocket and neither pose induced the folded P-loop conformation, 
most likely due to steric effects with P-loop residue Phe48 (Fig. 5d,e).
Structural comparisons of the solution NMR structure, where residues (346–354) within the C-terminal reg-
ulatory tail occupy the ATP-binding pocket, and the ligand-bound VRK1 structures obtained here reveal that 
changes in the ATP-binding site are mostly limited to the protein DYG motif and to the P-loop. Overall, binding 
of small molecule inhibitors to VRK1 repositioned the catalytic lysine to facilitate the formation of an ion pair 
between this residue and the conserved glutamate residue from αC, one of the hallmarks of the kinase active 
conformation (Figs 5b and f and Supplementary Figure S2).
Discussion
VRKs are implicated as mediators of a number of cellular processes and as potential therapeutic targets. But 
direct evidence for the roles of VRK1 and VRK2 in both disease and normal biology will be best derived from use 
of potent and selective pharmacological inhibitors of each active VRK38, 39. The crystal structures obtained here 
are the first example of ligand-bound VRK proteins. These structures expand our understanding on how these 
kinases interact with small-molecule ligands and reveal possible specificity determinants that can be explored by 
new inhibitors.
We found that the intrinsically active conformation of VRKs can be exploited to develop specific and potent 
compounds based on the dihydropteridinone scaffold. At 100 nM BI-D1870 was shown to inhibit all four RSK iso-
forms (1–4) (>98%) while also having activity against PLK1 (83%) and other six kinases (40–70%) in a 54-kinase 
selectivity panel, including CDK2 and CK132. Our data show that BI-D1870 also targets the active VRKs and that 
this compound could serve as an advanced starting point for a specific inhibitor of these proteins.
The structures of RSK2/BI-D1870 (PDB:5D9K)40 and of PLK bound to a similar compound (BI-D2536)
(PDB:2RKU)41 suggest that these proteins interact to the dihydropteridinone chemotype in a different way to the 
VRKs (Fig. 6). Our structure of BI-D1870 bound to the constitutively-active conformation of the VRKs revealed 
Figure 3. Co-crystal structures of ligand-bound active VRKs. Cartoon representation of VRK13-364 bound 
to (a) BI-D1870, (b) ASC24 and (c) GW297361X. (d) VRK214-335 in complex with BI-D1870. Positions of αC 
(in yellow), DYG motif (Cαs shown as salmon spheres), αC4 (in blue) and P-loop (in red) are indicated. (e) 
Superposition of VRK13-364/GW297361X, VRK214-335/BI-D1870 and CK1 (PDB:1CKJ). Small molecule ligands 
are shown in stick model (carbon atoms in yellow; nitrogen atoms in blue, oxygen atoms in red and sulfur atoms 
in dark green). (f) Superposition of individual polypeptide chains in VRK13-364/ligand co-crystals (colors as in 
panels a–d). (g) Superposition of VRK13-364/GW297361X to the solution NMR structure (PDB:2LAV - in gray; 
residues 1-20 and 357–361 omitted for clarity). The position of the regulatory C-terminal tail (in dark blue) is 
indicated. (h) Superposition of apo- (in gray) and BI-D1870-bound VRK214-335. In panels e–h, αC, αC4 and 
P-loop are show in cartoon representation, Cαs for residues within the DYG motif are shown as spheres and the 
rest of the polypeptide chain is shown as ribbons. Superpositions were performed using C-terminal residues 
only (residues 141–341 in VRK1).
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that BI-D1870 binds to polar residues in αC that are not available in RSK2 and PLK1. We also found that the Tyr 
residue adjacent to the conserved glutamic acid in αC in the VRKs is substituted by aliphatic residues unable to 
form hydrogen bonds in most of the known BI-D1870 off-targets (notable exceptions include CK1, PLK1 and 
AurB, which have tyrosine, histidine or glutamine residues in this position). Thus, our data suggest that replace-
ment of the hydroxyl group in the difluoro ring of BI-D1870 with a strong hydrogen-bond acceptor may improve 
the interaction of the compound with the active VRK proteins and increase its specificity over the RSKs. Our 
analysis of the PKIS results also suggested the importance of a hydrogen-bond acceptor in this position. However, 
the energetic penalty for the potential water molecule displacement with larger substituents should be taken into 
consideration in order to increase potency.
We also found that the stereogenic center in BI-D1870 might be explored to introduce specificity within the 
active VRKs. BI-D1870 is available as a racemic mixture but VRK2/BI-D1870 co-crystals favored a single enan-
tiomer (S-form), in which the methyl group attached at the stereogenic center interacts with the protein P-loop. 
The co-structures of VRK1 bound to ASC24 and GW297361X suggest this protein can accommodate larger 
groups in this position. Thus, to generate a VRK1 selective series, we may extend or replace the methyl chain in 
the S-isomer. Likewise, the extension of the methyl group in the R-form may prevent interaction with VRK2, 
while still allowing interactions with polar and charged groups at the binding pocket entrance in VRK1 (Asp137, 
Gln139, Lys140, Asn182, Lys179, Asp137 - VRK1 numbering). The apparent preference of VRK2 for a single 
enantiomer may aid in the development of a negative control compound for a VRK selective chemical probe38.
A promising feature of the ligand-bound VRK structures is the ability to adopt a folded conformation of 
the P-loop. This conformation has been associated with favorable inhibitor selectivity and has been observed 
for a number of protein kinases including major drug targets such as ABL1, Aurora A, FGFR1, cMET, p38 and 
MAP4K437, 42. The P-loop Tyr/Phe residue usually engages in aromatic stacking interactions, similar to the 
sulfur-π observed for VRK1/GW297361X structure. We propose that this interaction could be further explored 
to design a VRK1-specific inhibitor, as an equivalent interaction is unlikely to be supported by the folded confor-
mation of VRK2 P-loop. For example, the extension of the difluorinated ring to incorporate a sulfur-containing 
group, akin to the thiazole moiety in GW297361X may increase selectivity for VRK1. The highly dynamic 
N-terminal domain of VRK1 may also allow inhibitors to be accommodated in the observed gap between the 
P-loop and αC, akin to the recently-described binding mechanism of Erk1/2 inhibitor SCH77298443.
Although BI-D1870 is a good starting point for compounds targeting the active VRKs, development of specific 
inhibitors will require the elimination of cross-reactivity not only to other protein kinases, such as CDK2 and 
TNIK - identified in our HCL analyses; but also to un-anticipated off-targets. BI-D1870 interacts with the bromo-
domain of BRD4 with nanomolar affinity44. Thus, future compound development strategies will also incorporate 
Figure 4. Ligand-induced, P-loop-folded conformation in active VRKs. (a,c) Cartoon and (b,d) surface 
representations of the P-loop region in VRK13-364/GW297361X co-crystal. Dashed line in panel a indicates a 
sulfur-π interaction between the sulfur atom in the thiazole ring from the ligand and P-loop residue Phe48. 
Dashed line in panel d indicates a cavity between αC and P-loop exclusive to VRK1. (e,g) Cartoon and (f,h) 
surface representations of the P-loop region in VRK214–335/BI-D1870. Views in (a,b and e,f) are rotated ~90° 
from those in (c,d and g,h) respectively.
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selectivity features identified from the structures of VRK1 bound to the promiscuous compounds ASC24 and 
GW297361X, such as the P-loop interaction of ASC24 acetonitrile moiety and the ability of this protein to accom-
modate compounds in a tear-drop conformation.
Methods
Cloning, Expression, Purification and Crystallization. VRK13-364 and VRK214-335, appended with a 
tobacco etch virus (TEV) protease-cleavable, N-terminal 6xHis tag, were expressed from vector pNIC28-Bsa445. 
To improve VRK1 crystallizability, four clusters of surface entropy reduction mutations (SER)34, 46 were engi-
neered into this protein: K34A/K35A/E36A; E212A/K214A/E215A; E292A/K293A/K295A and K359A/K360A. 
For protein production, BL21(DE3)-R3 cells, including a plasmid expressing lambda phosphatase47, were cul-
tivated in TB medium (supplemented with 50 µg.ml−1 kanamycin, 35 µg.ml−1 chloramphenicol) at 37 °C until 
OD600 reached ~3 and then cooled to 18 °C for 1 hour. Isopropyl 1-thio-D-galactopyranoside (IPTG) was added 
to 0.1 mM, and growth continued at 18 °C overnight. Cells were collected by centrifugation and pellets suspended 
in 2x lysis buffer (lysis buffer is 50 mM HEPES buffer, pH 7.5, 0.5 M NaCl, 10 mM imidazole, 0.5 mM tris(2-car-
boxyethyl)phosphine [TCEP], Protease Inhibitors Cocktail Set VII - Calbiochem, 1/1000 dilution) prior to 
flash-freezing in liquid nitrogen. After thawing, cells were lysed by sonication on ice. Proteins were purified using 
Figure 5. Crystallographic details of ligand binding. (a) Interactions between VRK214-335 and BI-D1870. 
Arrows indicate re-arrangements of key residues compared to apo-VRK2 (PDB:2V62). (b) Interaction between 
VRK13-364 and GW297361X. The ligand sulfonamide group interacts with residues Ser136 and Lys140 at the 
C-terminal end of the hinge region. A green dashed line indicates a sulfur-π interaction between protein and 
ligand. (c) Interaction between VRK13-364 and ASC24. The ligand acetonitrile group interacts with main chain 
amide from Gln45 in the protein P-loop. (d,e) Interaction between VRK13-364 and BI-D1870. The ligand can 
adopt two distinct poses in VRK1 ATP-binding site. Electron density maps of the ligands (2Fo-Fc, contoured at 
1.0 σ) are shown below each structural model. (f) Structural comparison of VRK1 ATP-binding site in complex 
with the regulatory C-terminal tail (NMR structure, PDB:2LAV, in faded gray; the backbone of the C-terminal 
peptide is shown in blue) and with GW297361X. Arrows indicate re-arrangements of key residues compared 
to the solution VRK1 NMR structure. Black dashed lines indicate potential hydrogen bonds. Red spheres 
indicate ordered water molecules. Cαs of residues within the DYG motif are shown as spheres. In panels c–e, 
the position of Phe48 from VRK13-364/GW297361X is shown for comparison (in faded gray). Color scheme as in 
Fig. 3.
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Ni-Sepharose resin (GE Healthcare) and eluted stepwise in binding buffer with 300 mM imidazole. Removal of 
hexahistidine tags was performed at 4 °C overnight using recombinant TEV protease while dialyzing against 
excess gel filtration buffer (25 mM HEPES, 500 mM NaCl, 0.5 mM TCEP, 5% [v/v] glycerol). Proteins were fur-
ther purified by reverse affinity in Ni-Sepharose followed by gel filtration (Superdex 200 16/60, GE Healthcare). 
Protein in gel filtration buffer was concentrated to 14 mg.ml−1 (VRK13-364) or 20 mg.ml−1 (VRK214–335) using 
30 kDa MWCO centrifugal concentrators (Millipore) at 4 °C. Compounds in 100% DMSO were added to protein 
solutions at 3-fold molar excess and incubated on ice for approximately 30 minutes. This mixture was centrifuged 
at 14,000 rpm for 10 minutes at 4 °C prior to setting up 150-nl volume sitting drops at three ratios of protein-in-
hibitor complex to reservoir solution (2:1, 1:1, or 1:2). Crystallization experiments were performed at 20 °C. 
Crystals were cryoprotected in reservoir solution supplemented with 20–25% glycerol before flash-freezing in 
liquid nitrogen for data collection. Diffraction data were collected at the Diamond Light Source (DLS) or at 
the Laboratório Nacional de Luz Síncrotron (LNLS). The best-diffracting crystals grew under the conditions 
described in Table 2. Crystal optimization used Newman’s buffer system48.
Structure Solution and Refinement. Diffraction data were integrated using XDS49 and scaled using 
AIMLESS from the CCP4 software suite50. Molecular replacement (MR) for VRK13-364/ASC24 was performed 
with Phaser51 using an ensemble of the following proteins apo-VRK2 (PDB:2V62), apo-VRK3 (PDB:2JII)25 
and CSK1 (PDB:1CKJ)35. The VRK13-364/ASC24 structure was used as MR search model for phasing the other 
two VRK/ligand datasets. The apo-VRK2 structure (PDB:2V62)25 was used as MR search model for the VRK2/
BI-D1870 dataset. Automated model building was performed with Buccanner52 following density modification 
with Parrot53. Automated refinement was performed in PHENIX53. Coot54 was used for manual model building 
and refinement. Structure validation was performed using MolProbity55. Structure factors and coordinates have 
been deposited in the PDB (see Table 2).
Differential scanning fluorimetry (DSF). Thermal stabilization assays were performed as described28, 
56. Purified VRK13-364 and VRK214-335 were screened against a library of 378 structurally diverse, cell permeable 
ATP-competitive kinase inhibitors purchased from Selleckchem (Houston, TX, USA; catalog No. L1200). DSF 
Figure 6. Active VRKs, PLK1 and RSK2 have dissimilar binding modes to pteridinone compounds. (a,b) BI-
D1870 has two distinct binding modes to VRK1, supported by different interactions with the protein hinge 
region. (c) BI-D1870 interaction with VRK2. Both VRK1 and VRK2 are constitutively in a DFG-in, active 
conformation. (d) RSK2 binds to BI-D1870 in an inactive, DFG-out conformation (PDB:5DK9). (e) BI-D2536 
binding mode to PLK1 (PDB:2RKU) is similar to pose 2 in VRK13-364/BI-D1870 co-crystals. PLK1 residues 
at the back of the ATP-binding site (K82, E101 and D194) contact the compound via an extensive network of 
water-mediated hydrogen bonds. Side chains of Asp and Tyr/Phe residues from the DFG (DYG in the VRKs) are 
shown in stick representations; Cαs in these residues are shown as spheres (salmon).
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experiments were performed in a 384-well plate format. Each well contained 25 μL of 1 μM kinase in potas-
sium phosphate buffer and the Protein Thermal Shift dye at the recommended concentration of 1:1000 (Applied 
Biosystems; the composition of the buffer and the dye solutions are not disclosed). Compounds (10 mM) in 
DMSO were added to 16 μM final concentration to complete a total assay volume of 25.8 μL (3.1% final DMSO). 
Plates were sealed using optically clear films and transferred to a QuantStudio 6 qPCR instrument (Applied 
Biosystems). Fluorescence intensity data were acquired in a temperature gradient from 25 to 95 °C at a constant 
rate of 0.05 °C/sec and protein melting temperatures were calculated based on a Boltzmann function fitting to 
experimental data, as implemented in the Protein Thermal Shift Software (Applied Biosystems). Protein in 3.1% 
DMSO was used as a reference.
Data availability. PDB accession codes are 3OP5 (VRK13-364/ASC24), 5UU1 (VRK214-335/BI-D1870); 5UVF 
(VRK13-364/BI-D1870) and 5UKF (VRK139-364/GW297361X).
References
 1. Boyle, K. A. & Traktman, P. Members of a novel family of mammalian protein kinases complement the DNA-negative phenotype of 
a vaccinia virus ts mutant defective in the B1 kinase. J Virol 78, 1992–2005 (2004).
 2. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 
298, 1912–1934 (2002).
 3. Nezu, J., Oku, A., Jones, M. H. & Shimane, M. Identification of two novel human putative serine/threonine kinases, VRK1 and 
VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics 45, 327–331 (1997).
 4. Noble, M. E., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 303, 
1800–1805 (2004).
 5. Scheeff, E. D. & Bourne, P. E. Structural evolution of the protein kinase-like superfamily. PLoS computational biology 1, e49 (2005).
 6. Vega, F. M., Gonzalo, P., Gaspar, M. L. & Lazo, P. A. Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators 
in murine hematopoietic development. FEBS letters 544, 176–180 (2003).
 7. Kang, T. H. et al. Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Molecular and cellular biology 
27, 8533–8546 (2007).
 8. Kang, T. H., Park, D. Y., Kim, W. & Kim, K. T. VRK1 phosphorylates CREB and mediates CCND1 expression. Journal of cell science 
121, 3035–3041 (2008).
 9. Lopez-Borges, S. & Lazo, P. A. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 
binding site of the p53 tumour suppressor protein. Oncogene 19, 3656–3664 (2000).
 10. Nichols, R. J. & Traktman, P. Characterization of three paralogous members of the Mammalian vaccinia related kinase family. The 
Journal of biological chemistry 279, 7934–7946 (2004).
 11. Sevilla, A., Santos, C. R., Barcia, R., Vega, F. M. & Lazo, P. A. c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) 
and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene 23, 8950–8958 (2004).
 12. Sevilla, A., Santos, C. R., Vega, F. M. & Lazo, P. A. Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional 
activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK. The Journal of biological chemistry 279, 
27458–27465 (2004).
 13. Valbuena, A. et al. Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. Lung Cancer 58, 303–309 (2007).
 14. Vega, F. M., Sevilla, A. & Lazo, P. A. p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. Molecular and 
cellular biology 24, 10366–10380 (2004).
 15. Molitor, T. P. & Traktman, P. Molecular genetic analysis of VRK1 in mammary epithelial cells: depletion slows proliferation in vitro 
and tumor growth and metastasis in vivo. Oncogenesis 2, e48 (2013).
 16. Salzano, M. et al. Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting 
DNA damage response. Oncotarget 5, 1770–1778 (2014).
 17. Santos, C. R. et al. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. 
Mol Cancer Res 4, 177–185 (2006).
 18. Blanco, S., Klimcakova, L., Vega, F. M. & Lazo, P. A. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms 
determines their different effect on p53 stability in tumour cell lines. FEBS J 273, 2487–2504 (2006).
 19. Blanco, S., Santos, C. & Lazo, P. A. Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. Molecular 
and cellular biology 27, 7273–7283 (2007).
 20. Blanco, S., Sanz-Garcia, M., Santos, C. R. & Lazo, P. A. Modulation of interleukin-1 transcriptional response by the interaction 
between VRK2 and the JIP1 scaffold protein. PloS one 3, e1660 (2008).
 21. Li, L. Y., Liu, M. Y., Shih, H. M., Tsai, C. H. & Chen, J. Y. Human cellular protein VRK2 interacts specifically with Epstein-Barr virus 
BHRF1, a homologue of Bcl-2, and enhances cell survival. J Gen Virol 87, 2869–2878 (2006).
 22. Nichols, R. J., Wiebe, M. S. & Traktman, P. The vaccinia-related kinases phosphorylate the N’ terminus of BAF, regulating its 
interaction with DNA and its retention in the nucleus. Molecular biology of the cell 17, 2451–2464 (2006).
 23. Monsalve, D. M. et al. Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expression. Cell 
Death Dis 4, e513 (2013).
 24. Kang, T. H. & Kim, K. T. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. Nature cell biology 
8, 863–869 (2006).
 25. Scheeff, E. D., Eswaran, J., Bunkoczi, G., Knapp, S. & Manning, G. Structure of the pseudokinase VRK3 reveals a degraded catalytic 
site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17, 128–138 (2009).
 26. Shin, J. et al. NMR solution structure of human vaccinia-related kinase 1 (VRK1) reveals the C-terminal tail essential for its 
structural stability and autocatalytic activity. The Journal of biological chemistry 286, 22131–22138 (2011).
 27. Barcia, R., Lopez-Borges, S., Vega, F. M. & Lazo, P. A. Kinetic properties of p53 phosphorylation by the human vaccinia-related 
kinase 1. Arch Biochem Biophys 399, 1–5 (2002).
 28. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National 
Academy of Sciences of the United States of America 104, 20523–20528 (2007).
 29. Elkins, J. M. et al. Comprehensive characterization of the Published Kinase Inhibitor Set. Nature biotechnology 34, 95–103 (2016).
 30. Graczyk, P. P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. Journal of medicinal 
chemistry 50, 5773–5779 (2007).
 31. Bramson, H. N. et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and 
X-ray crystallographic analysis. Journal of medicinal chemistry 44, 4339–4358 (2001).
 32. Sapkota, G. P. et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. The 
Biochemical journal 401, 29–38 (2007).
 33. Statsuk, A. V. et al. Tuning a three-component reaction for trapping kinase substrate complexes. Journal of the American Chemical 
Society 130, 17568–17574 (2008).
 34. Derewenda, Z. S. Rational protein crystallization by mutational surface engineering. Structure 12, 529–535 (2004).
www.nature.com/scientificreports/
1 2SCIENtIFIC RepoRtS | 7: 7501  | DOI:10.1038/s41598-017-07755-y
 35. Longenecker, K. L., Roach, P. J. & Hurley, T. D. Three-dimensional structure of mammalian casein kinase I: molecular basis for 
phosphate recognition. Journal of molecular biology 257, 618–631 (1996).
 36. Kornev, A. P. & Taylor, S. S. Defining the conserved internal architecture of a protein kinase. Biochimica et biophysica acta 1804, 
440–444 (2010).
 37. Guimaraes, C. R. et al. Understanding the impact of the P-loop conformation on kinase selectivity. Journal of chemical information 
and modeling 51, 1199–1204 (2011).
 38. Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nature chemical biology 11, 536–541 (2015).
 39. Uitdehaag, J. C. et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug 
targets. British journal of pharmacology 166, 858–876 (2012).
 40. Jain, R. et al. Discovery of Potent and Selective RSK Inhibitors as Biological Probes. Journal of medicinal chemistry 58, 6766–6783 (2015).
 41. Kothe, M. et al. Selectivity-determining residues in Plk1. Chemical biology & drug design 70, 540–546 (2007).
 42. Hari, S. B., Perera, B. G., Ranjitkar, P., Seeliger, M. A. & Maly, D. J. Conformation-selective inhibitors reveal differences in the 
activation and phosphate-binding loops of the tyrosine kinases Abl and Src. ACS chemical biology 8, 2734–2743 (2013).
 43. Chaikuad, A. et al. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nature chemical biology 10, 
853–860 (2014).
 44. Ciceri, P. et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nature chemical biology 10, 305–312 
(2014).
 45. Savitsky, P. et al. High-throughput production of human proteins for crystallization: the SGC experience. J Struct Biol 172, 3–13 (2010).
 46. Goldschmidt, L., Cooper, D. R., Derewenda, Z. S. & Eisenberg, D. Toward rational protein crystallization: A Web server for the 
design of crystallizable protein variants. Protein Sci 16, 1569–1576 (2007).
 47. Shrestha, A., Hamilton, G., O’Neill, E., Knapp, S. & Elkins, J. M. Analysis of conditions affecting auto-phosphorylation of human 
kinases during expression in bacteria. Protein Expr Purif 81, 136–143 (2012).
 48. Newman, J. Novel buffer systems for macromolecular crystallization. Acta crystallographica. Section D, Biological crystallography 60, 
610–612 (2004).
 49. Kabsch, W. X. Acta crystallographica. Section D, Biological crystallography 66, 125–132 (2010).
 50. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta crystallographica. Section D, Biological crystallography 
67, 235–242 (2011).
 51. McCoy, A. J. et al. Phaser crystallographic software. Journal of applied crystallography 40, 658–674 (2007).
 52. Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein chains. Acta crystallographica. Section D, 
Biological crystallography 62, 1002–1011 (2006).
 53. Zhang, K. Y., Cowtan, K. & Main, P. Combining constraints for electron-density modification. Methods in enzymology 277, 53–64 (1997).
 54. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta crystallographica. Section D, Biological 
crystallography 66, 486–501 (2010).
 55. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Section D, 
Biological crystallography 66, 12–21 (2010).
 56. Niesen, F. H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote 
protein stability. Nat Protoc 2, 2212–2221 (2007).
Acknowledgements
SGC, a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer 
Ingelheim, the Canada Foundation for Innovation, Genome Canada, GlaxoSmithKline, Janssen, Lilly Canada, 
Merck & Co., the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, 
Pfizer, the São Paulo Research Foundation (FAPESP grant 13/50724-5), Takeda, EU/EFPIA Innovative Medicines 
Initiative (IMI) Joint Undertaking (ULTRA-DD grant 115766) and the Wellcome Trust (092809/Z/10/Z). We 
thank Diamond Light Source for access to beam line I02 (proposal number MX12988-1) and I03 (proposal 
number MX10619-74) and beam line scientists Dr. Juan Sanchez-Weatherby and Dr. Carina Lobley who assisted 
with data collection. We also thank LNLS for access to beam line MX2 and beam line scientists Dr. Luciano 
Candido and Dr. Alexandre Lo Bianco Dos Santos who assisted with data collection. We thank Dr. Ricardo A.M. 
Serafim for help in preparing the SAR figure and Dr. Aled M. Edwards for critical review of the manuscript.
Author Contributions
P.S. and O.G. performed and analyzed the molecular biology experiments. P.H.G. and O.G. designed, performed 
and analyzed the D.S.F. experiments. R.M.C. and C.K.A. designed and performed the crystallography and 
structural biology experiments. R.M.C., H.A. and C.K.A. analyzed the protein structures. C.I.W. and W.J.Z. 
performed initial PKIS analyses. H.A., A.M., F.H.S.G. and C.R.W.G. performed the PKIS analyses including the 
H.C.L., S.A.R. and Gini coefficient determination. O.G., R.M.C. and H.A. wrote the manuscript. K.B.M. helped 
coordinate and design the project. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-07755-y
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
